Molecular predictors of response to tyrosine kinase inhibitors in patients with Non-Small-Cell Lung Cancer

被引：0
|
作者：
Samuel Murray
Vasilios Karavasilis
Mattheos Bobos
Evangelia Razis
Savvas Papadopoulos
Christos Christodoulou
Paris Kosmidis
George Fountzilas
机构：
[1] BioMarker Solutions Ltd,Department of Molecular Oncology
[2] GeneKOR,Department of Medical Oncology
[3] “Papageorgiou” Hospital,Department of Pathology
[4] Aristotle University of Thessaloniki School of Medicine,First Department of Medical Oncology
[5] Aristotle University of Thessaloniki School of Medicine,Department of Pathology
[6] “Hygeia” Hospital,Second Department of Medical Oncology
[7] “Hygeia” Hospital,Second Department of Medical Oncology
[8] “Metropolitan” Hospital,undefined
[9] “Hygeia” Hospital,undefined
来源：
Journal of Experimental & Clinical Cancer Research | / 31卷
关键词：
Predictive; Somatic mutation; EGFR; Gefitinib; Erlotinib; Response;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Molecular predictors of response to tyrosine kinase inhibitors in patients with Non-Small-Cell Lung Cancer
    Murray, Samuel
    Karavasilis, Vasilios
    Bobos, Mattheos
    Razis, Evangelia
    Papadopoulos, Savvas
    Christodoulou, Christos
    Kosmidis, Paris
    Fountzilas, George
    JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2012, 31
  • [2] Clinical and molecular predictors of response to EGFR tyrosine kinase inhibitors in non-small cell lung cancer
    Rouge, Thibault de La Motte
    Valent, Alexander
    Ambrosetti, Damien
    Vielh, Philippe
    Lacroix, Ludovic
    ANNALES DE PATHOLOGIE, 2007, 27 (05) : 353 - 363
  • [3] Chasing targets for EGFR tyrosine kinase inhibitors in non-small-cell lung cancer: Asian perspectives
    Kim, Toe-You
    Han, Soe-Won
    Bang, Yung-Jue
    EXPERT REVIEW OF MOLECULAR DIAGNOSTICS, 2007, 7 (06) : 821 - 836
  • [4] Clinical Predictors of Response to EGFR Tyrosine Kinase inhibitors in Patients with EGFR-Mutant Non-Small Cell Lung Cancer
    Fukihara, Jun
    Watanabe, Naohiro
    Taniguchi, Hiroyuki
    Kondoh, Yasuhiro
    Kimura, Tomoki
    Kataoka, Kensuke
    Matsuda, Toshiaki
    Yokoyama, Toshiki
    Hasegawa, Yoshinori
    ONCOLOGY, 2014, 86 (02) : 86 - 93
  • [5] Second-line treatment of non-small-cell lung cancer: chemotherapy or tyrosine kinase inhibitors?
    Passaro, Antonio
    Cortesi, Enrico
    de Marinis, Filippo
    EXPERT REVIEW OF ANTICANCER THERAPY, 2011, 11 (10) : 1587 - 1597
  • [6] Strategies to overcome resistance to tyrosine kinase inhibitors in non-small-cell lung cancer
    Santarpia, Mariacarmela
    Gil, Nuno
    Rosell, Rafael
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2015, 8 (04) : 461 - 477
  • [7] Protein kinase inhibitors to treat non-small-cell lung cancer
    Minuti, Gabriele
    D'Incecco, Armida
    Landi, Lorenza
    Cappuzzo, Federico
    EXPERT OPINION ON PHARMACOTHERAPY, 2014, 15 (09) : 1203 - 1213
  • [8] EGFR-Mutant Non-Small-Cell Lung Cancer at Surgical Stages: What Is the Place for Tyrosine Kinase Inhibitors?
    Cansouline, Xavier
    Lipan, Beatrice
    Sizaret, Damien
    Tallet, Anne
    Vandier, Christophe
    Carmier, Delphine
    Legras, Antoine
    CANCERS, 2022, 14 (09)
  • [9] Mechanisms of Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients with Advanced Non-Small-Cell Lung Cancer: Clinical and Molecular Considerations
    Pallis, A.
    Briasoulis, E.
    Linardou, H.
    Papadimitriou, C.
    Bafaloukos, D.
    Kosmidis, P.
    Murray, S.
    CURRENT MEDICINAL CHEMISTRY, 2011, 18 (11) : 1613 - 1628
  • [10] Predictors of response in EGFR-mutant metastatic non-small cell lung cancer patients treated with tyrosine kinase inhibitors
    Dogan, Izzet
    Khanmammadov, Nijat
    Yildiz, Anil
    Ahmed, Melin Aydan
    Vatansever, Sezai
    Saip, Pinar
    Aydiner, Adnan
    JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2023, 19 (07) : 1945 - 1949
12345